Inozyme Pharma Inc (INZY)

May 02, 2025

JPMorgan Chase & Co. Acquires 99,944 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

May 02, 2025

May 01, 2025

Inozyme Pharma Inc’s Shares Reel: -19.01% Quarterly Revenue Decline Amid 73.87M Market Cap - investchronicle.com

May 01, 2025

May 01, 2025

INZY Stock Sees Surge of Approximately 17.28% in Last Five Days - knoxdaily.com

May 01, 2025

May 01, 2025

Are Inozyme Pharma Inc’shares a good deal? - uspostnews.com

May 01, 2025

Apr 30, 2025

Eventide Asset Management, LLC Reduces Stake in Inozyme Pharma I - GuruFocus

Apr 30, 2025

Apr 30, 2025

Renaissance Technologies LLC Buys 256,599 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Apr 30, 2025

Apr 24, 2025

Inozyme Pharma Inc [NASDAQ: INZY] Sees Decrease in Stock Value - knoxdaily.com

Apr 24, 2025

Apr 24, 2025

Financial Snapshot: Analyzing Inozyme Pharma Inc (INZY)’s Key Ratio Metrics - DWinneX

Apr 24, 2025

Apr 20, 2025

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Apr 20, 2025

Apr 19, 2025

Is Now A Good Time To Invest In Inozyme Pharma Inc (NASDAQ: INZY)? - Stocksregister

Apr 19, 2025

Apr 15, 2025

Wellington Management Group LLP Lowers Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Apr 15, 2025

Apr 12, 2025

Raymond James Financial Inc. Invests $205,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Apr 12, 2025

Apr 12, 2025

Inozyme Pharma Inc (NASDAQ: INZY) Has Fallen -601.12% From Its Highs, What Comes Next? - Marketing Sentinel

Apr 12, 2025

Apr 11, 2025

H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com India

Apr 11, 2025

Apr 11, 2025

H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com

Apr 11, 2025

Apr 11, 2025

Inozyme Pharma (INZY) Publishes Comprehensive Study on ENPP1 Def - GuruFocus

Apr 11, 2025

Apr 11, 2025

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Rea - GuruFocus

Apr 11, 2025

Apr 10, 2025

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - The National Law Review

Apr 10, 2025

Apr 07, 2025

INZY stock touches 52-week low at $0.77 amid market challenges - Investing.com UK

Apr 07, 2025

Mar 31, 2025

Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan

Mar 31, 2025

Mar 31, 2025

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

Mar 31, 2025

Mar 26, 2025

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 26, 2025

Mar 22, 2025

Inozyme Pharma Inc (NASDAQ: INZY) Has Decreased By -82.88 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel

Mar 22, 2025

Mar 18, 2025

Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 18, 2025

Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia

Mar 18, 2025

Mar 15, 2025

FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World

Mar 15, 2025

Mar 14, 2025

Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World

Mar 14, 2025

Mar 14, 2025

Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World

Mar 14, 2025

Mar 14, 2025

Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World

Mar 14, 2025

Mar 13, 2025

Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World

Mar 13, 2025

Mar 13, 2025

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com

Mar 13, 2025

Mar 13, 2025

Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World

Mar 13, 2025

Mar 12, 2025

Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 12, 2025

Mar 12, 2025

Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 11, 2025

Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com

Mar 11, 2025

Mar 11, 2025

Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com

Mar 11, 2025

Mar 11, 2025

Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks

Mar 11, 2025

Mar 10, 2025

Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025

Mar 10, 2025

Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks

Mar 10, 2025

Mar 10, 2025

Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq

Mar 10, 2025

Mar 10, 2025

Inozyme Pharma, Inc. SEC 10-K Report - TradingView

Mar 10, 2025

Mar 10, 2025

Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider

Mar 10, 2025

Mar 10, 2025

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph

Mar 10, 2025